發(fā)布時(shí)間：2018-07-11 17:54

  本文選題：肝硬化 + 門靜脈血栓��； 參考：《山西醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:系統(tǒng)評(píng)價(jià)抗凝治療門靜脈血栓形成在肝硬化患者中的有效性及安全性。方法:計(jì)算機(jī)檢索Cochrane Library、PubMed、EMBASE、Web of Science、ScienceDirect及中國(guó)知網(wǎng)(CNKI)、維普數(shù)據(jù)庫(kù)和萬(wàn)方數(shù)據(jù)庫(kù)中有關(guān)肝硬化伴門靜脈血栓形成接受抗凝治療的臨床對(duì)照研究,對(duì)檢索到的文獻(xiàn)進(jìn)行篩選、質(zhì)量評(píng)價(jià)及資料數(shù)據(jù)提取;采用Review Manager 5.3.5軟件對(duì)數(shù)據(jù)進(jìn)行Meta分析。計(jì)數(shù)資料采用比值比(odds ratio,OR)及95%可信區(qū)間(95%confidence interval,95%CI)。結(jié)果:共納入7篇文獻(xiàn),均為臨床對(duì)照研究,合計(jì)343例肝硬化并發(fā)有門靜脈形成的患者,其中抗凝治療187例,未抗凝治療156例。薈萃分析結(jié)果顯示:在肝硬化并門脈血栓的患者中,門靜脈的再通率情況抗凝組高于對(duì)照組[OR=7.31,95%CI(4.15,12.87),Z=6.89,P0.00001],出血等不良事件發(fā)生率在抗凝組與對(duì)照組間差異無(wú)統(tǒng)計(jì)學(xué)意義[OR=0.36,95%CI(0.07,1.91),Z=1.20,P=0.23]。結(jié)論:抗凝治療肝硬化患者的門脈血栓是有效的,但其安全性方面仍尚待進(jìn)一步研究。
[Abstract]:Objective: to evaluate the efficacy and safety of anticoagulant therapy for portal vein thrombosis in cirrhotic patients. Methods: the clinical controlled studies on anticoagulant therapy of cirrhotic patients with portal vein thrombosis were searched on the Cochrane Library PubMeden Web of Science Science Direct and CNKI, Weip database and Wanfang database. Quality evaluation and data extraction; Meta-analysis of data by Review Manager 5.3.5 software. Odds ratioor and 95% CI were used. Results: a total of 7 articles were included in this study. 343 patients with cirrhosis complicated with portal vein formation were included in this study. 187 cases were treated with anticoagulant therapy and 156 cases were treated with no anticoagulant therapy. The results of meta-analysis showed that the recanalization rate of portal vein in patients with cirrhosis and portal vein thrombosis was higher than that in the control group [OR7.31 鹵95CI (4.15 鹵12.87)]. The incidence of adverse events such as hemorrhage had no significant difference between the anticoagulant group and the control group [OR0.36 9595 CI (0.071.91) CI (0.071.91)]. Conclusion: anticoagulant therapy for portal thrombosis in patients with liver cirrhosis is effective, but its safety remains to be further studied.
【學(xué)位授予單位】：山西醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R575.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前6條

1 薛帥;張強(qiáng);劉嘉;王培松;陳光;;斷流術(shù)后門靜脈血栓的診療現(xiàn)狀[J];世界華人消化雜志;2016年29期

2 陸申新;陳世耀;;抗凝治療肝硬化患者并發(fā)門靜脈血栓的循證醫(yī)學(xué)證據(jù)[J];實(shí)用肝臟病雜志;2016年05期

3 彭穎;祁興順;郭曉鐘;;《2016年意大利肝病學(xué)會(huì)和意大利醫(yī)學(xué)學(xué)會(huì)共識(shí):肝硬化止血平衡》推薦意見[J];臨床肝膽病雜志;2016年06期

4 高帆;胡鳳蓉;祁興順;;《2015年歐洲肝病學(xué)會(huì)臨床實(shí)踐指南:肝臟血管病》摘譯[J];臨床肝膽病雜志;2016年01期

5 Damian J Harding;M Thamara PR Perera;Frederick Chen;Simon Olliff;Dhiraj Tripathi;;Portal vein thrombosis in cirrhosis: Controversies and latest developments[J];World Journal of Gastroenterology;2015年22期

6 馬婧]，

本文編號(hào)：2116145